abstract |
The present invention relates to a cell medicament containing mesenchymal stem cells and a method for manufacturing the same. More specifically, it is a cell medicament containing mesenchymal stem cells, a) the mesenchymal stem cells express CX3CL1 by stimulation of inflammatory cytokines, and/or b) 90% of the mesenchymal stem cells Cell medicament in which the abnormality expresses EGFR and/or ITGA4, and a method for manufacturing a cell medicament comprising mesenchymal stem cells, a) by adding inflammatory cytokines to a culture containing mesenchymal stem cells , A process comprising confirming that mesenchymal stem cells express CX3CL1, and/or b) a method of confirming that at least 90% of mesenchymal stem cells express EGFR and/or ITGA4 will be. |